Published on
April 24, 2025
- 14:30 GMT
Affini-T Therapeutics Presents Preclinical Data from its Programs Targeting Oncogenic Drivers KRAS and TP53 at AACR
BOSTON, MA, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- Affini-T Therapeutics to present data from pipeline programs targeting the cancer driver mutations KRAS G12V and TP53 R175H. Presentations will include real-world data on the low frequency …
Distribution channels:
Banking, Finance & Investment Industry, Conferences & Trade Fairs
...
